JNJ Stock Dips After Hitting All-Time High Amid Sector Volatility

Johnson & Johnson's stock took a hit on September 8, 2026, after hitting an all-time high. The company's shares closed at $268.82 on the New York Stock Exchange, down 2.33 percent from the prior close.

The dip follows stronger-than-expected results for Q2 2026, with worldwide sales reaching $25.3 billion, up 5.6 percent operationally versus the prior year. The Innovative Medicine segment contributed $16.4 billion to this growth.

Oncology therapies remained a key driver of growth in Q2 2026, with Darzalex sales exceeding $4 billion and Tremfya reaching $2 billion, growing 71 percent year-on-year.